Menu Search
Equities

Rainmed Medical Ltd

2297:HKG.HZ

Rainmed Medical Ltd

Actions
  • Price (HKD)0.31
  • Today's Change0.00 / 0.00%
  • Shares traded2.00k
  • 1 Year change-67.37%
  • Beta--
Data delayed at least 15 minutes, as of May 21 2024 03:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rainmed Medical Ltd is a China-based investment holding company. The Company is primarily engaged in research and development, manufacturing and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) system and coronary angiography-derived index of microvascular resistance (caIMR) system. The Company’s core products, caFFR system and caIMR system, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)78.95m
  • Net income in HKD-124.90m
  • Incorporated2014
  • Employees354.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.